{"id":386438,"date":"2020-11-23T05:35:53","date_gmt":"2020-11-23T10:35:53","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386438"},"modified":"2020-11-23T05:35:53","modified_gmt":"2020-11-23T10:35:53","slug":"ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/","title":{"rendered":"Ascentage Pharma Receives Approvals for Two Phase Ib\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>SUZHOU, <span class=\"xn-location\">China<\/span> and ROCKVILLE, <span id=\"spanHghlt092b\">Md.<\/span>, Nov.<span id=\"spanHghlt9740\">\u00a023<\/span>, 2020 \/PRNewswire\/ &#8212; Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved two Phase Ib\/II clinical studies of its novel Bcl-2 inhibitor APG-2575; one for APG-2575 as a single agent or in combination with ibrutinib\/rituximab for the treatment of patients with Waldenstr\u00f6m macroglobulinemia (WM), and the other one for APG-2575 as a single agent or in combination with lenalidomide\/dexamethasone for the treatment of patients with multiple myeloma (MM).<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/891219\/Ascentage_Pharma_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/891219\/Ascentage_Pharma_Logo.jpg\" title=\"Ascentage Pharma Logo (PRNewsfoto\/Ascentage Pharma)\" alt=\"Ascentage Pharma Logo (PRNewsfoto\/Ascentage Pharma)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>APG-2575 is a novel, orally administered Bcl-2\u2012selective inhibitor being developed by Ascentage Pharma. APG-2575 is designed to treat several hematologic malignancies by selectively blocking Bcl-2 to restore the normal apoptosis process in cancer cells. APG-2575 is the first <span class=\"xn-location\">China<\/span>-developed Bcl-2 inhibitor having entered clinical development in <span class=\"xn-location\">China<\/span>. APG-2575 has received clearances and approvals for multiple Phase Ib\/II clinical studies in <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">Australia<\/span>, and the US, and is currently being developed in a range of hematologic malignancies globally. Of those studies, the Phase Ib\/II study of APG-2575 as a single agent or in combination with ibrutinib\/rituximab for the treatment of WM is a global multicenter trial with centers in <span class=\"xn-location\">Australia<\/span>, <span class=\"xn-location\">China<\/span>, and the US.<\/p>\n<ul type=\"disc\">\n<li>\n          <b>The Phase Ib\/II study of APG-2575 as a single agent or in combination with ibrutinib\/rituximab for the treatment of patients with WM<\/b>\n        <\/li>\n<\/ul>\n<p>This global multicenter, open-label Phase Ib\/II dose-expansion study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-2575 as a single agent or in combination with ibrutinib\/rituximab for the treatment of patients with WM.<\/p>\n<p>WM is a rare indolent B-cell lymphoma, accounting for &lt;2% of all non-Hodgkin&#8217;s lymphoma (NHL) cases. Treatment recommendations for WM from current guidelines suggest an objective response rate (ORR) of about 80% with contemporary therapies, but they deliver a very low rate of very good partial response (VGPR) or deeper responses (20% or lower), with most patients eventually relapsing or experiencing further disease progression. Furthermore, patients are diagnosed with WM at a median age of 70, when many individuals are intolerant of aggressive therapies because of poor health conditions, hence presenting an urgent clinical need for more effective therapies<sup><span id=\"spanHghlt9850\">[1]<\/span><\/sup>.<\/p>\n<p>Preclinical study data of APG-2575 have shown responses generated in WM models resistant or insensitive to ibrutinib, as well as the synergistic effect with ibrutinib in various models of NHL, including follicular lymphoma, diffuse large B-cell lymphoma, and WM.<\/p>\n<ul type=\"disc\">\n<li>\n          <b>The Phase Ib\/II study of APG-2575 as a single agent or in combination with lenalidomide\/dexamethasone for the treatment of patients with MM<\/b>\n        <\/li>\n<\/ul>\n<p>This multicenter, open-label Phase Ib\/II dose-escalation study to be carried out in <span class=\"xn-location\">China<\/span> is designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of APG-2575 as a single agent or in combination with lenalidomide\/dexamethasone in patients with relapsed\/refractory MM.<\/p>\n<p>MM is a plasma cell proliferative disorder with manifestations like hypercalcemia, anemia, renal failure, and bone disease. MM remains incurable. As reported, MM accounts for about 1.8% of all malignant tumors and 18.2% of all hematopoietic neoplasms. MM is the second most common hematological malignancy<sup><span id=\"spanHghltd311\">[2]<\/span><\/sup>. The age-standardized incidence rate of MM in the US is approximately 6.9 per 100,000<sup><span id=\"spanHghlt37f4\">[3]<\/span><\/sup>. The incidence rate of MM in <span class=\"xn-location\">China<\/span> has increased significantly in recent years, and the mortality rate increased with age, especially for patients over 60 years. The median age at diagnosis in <span class=\"xn-location\">China<\/span> is 59 years, much younger than US (~69 years). The incidence also increases with age. With an aging population and advanced diagnostic capabilities, the prevalence of MM is anticipated to keep growing in <span class=\"xn-location\">China<\/span><sup><span id=\"spanHghlta172\">[4]<\/span><\/sup>.<\/p>\n<p>In the preclinical studies of Ascentage Pharma, APG-2575 demonstrated potent antiproliferative activity in MM cell lines bearing the chromosomal t (11;14). I And in MM cell lines without t (11;14), the combinations with lenalidomide or pomalidomide and dexamethasone greatly enhanced APG-2575 cell sensitivity and triggered more potent cell death.<\/p>\n<p>&#8220;APG-2575 is a key drug candidate in our apoptosis-targeted pipeline, and the first <span class=\"xn-location\">China<\/span>-developed selective Bcl-2 small-molecule inhibitor, with great therapeutic potential as a single agent or in combinations in a range of hematologic malignancies including WM and MM,&#8221; said Dr. <span class=\"xn-person\">Yifan Zhai<\/span>, Chief Medical Officer of Ascentage Pharma. &#8220;There is a growing emphasis on combination therapy in cancer treatments. We will accelerate these studies of APG-2575 and strive to develop a new treatment option for patients in need.&#8221;<\/p>\n<div>\n<table id=\"convertedTable74e9\" cellspacing=\"0\" cellpadding=\"0\" border=\"1\" class=\"prntblns\">\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>References:<\/b><br \/>\n                <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <sup><br \/>\n                    <span id=\"spanHghltbc1b\" class=\"prnews_span\">[1]<\/span><br \/>\n                  <\/sup> NCCN Clinical Practice Guidelines in Oncology for Waldenstr\u00f6m Macroglobulinemia, Version 1.2020-December 6,2019<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <sup><br \/>\n                    <span id=\"spanHghlt7cad\" class=\"prnews_span\">[2]<\/span><br \/>\n                  <\/sup> Siegel, R. L., Miller, K. D., &amp; Jemal, A. (2019). Cancer statistics, 2019. CA: a cancer journal for clinicians, 69(1), 7-34.<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <sup><br \/>\n                    <span id=\"spanHghltf51d\" class=\"prnews_span\">[3]<\/span><br \/>\n                  <\/sup> Cancer Stat Facts: Myeloma; Surveillance, Epidemiology, and End Results Program, US National Cancer Institute. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html Accessed on 2020.3.18<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <sup><br \/>\n                    <span id=\"spanHghltaf69\" class=\"prnews_span\">[4]<\/span><br \/>\n                  <\/sup> Liu, J., Liu, W., Zeng, X., Ma, J., et al. Incidence and Mortality of Multiple Myeloma in China, 2006-2016: An Analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019; 12: 136.<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>\n        <b>About APG-2575<\/b>\n      <\/p>\n<p>APG-2575 is a novel, orally administered Bcl-2\u2012selective inhibitor being developed by Ascentage Pharma. APG-2575 is designed to treat a variety of hematologic malignancies by selectively blocking Bcl-2 to restore the normal apoptosis process in cancer cells. Ascentage Pharma has previously commenced Phase I studies of APG-2575 single agent in <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">Australia<\/span>, and <span class=\"xn-location\">the United States<\/span>. Since <span class=\"xn-chron\">March 2020<\/span>, the company has received approvals and clearances for several Phase Ib\/II studies of APG-2575 in <span class=\"xn-location\">China<\/span>, <span class=\"xn-location\">Australia<\/span>, and the US, and is advancing clinical development of APG-2575 for a variety of hematologic malignancy indications, including relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, Waldenstr\u00f6m macroglobulinemia, relapsed\/refractory multiple myeloma, and relapsed\/refractory acute myeloid leukemia. APG-2575 was recently granted two orphan drug designations by the US Food and Drug Administration in the treatment of Waldenstr\u00f6m Macroglobulinemia and Chronic Lymphocytic Leukemia.<\/p>\n<p>\n        <b>About Ascentage Pharma<\/b>\n      <\/p>\n<p>Ascentage Pharma (6855.HK) is a globally, clinical-stage biotechnology company engaged in developing novel therapies for cancers, CHB, and age-related diseases. On <span class=\"xn-chron\">October 28, 2019<\/span>, Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 6855.HK.<\/p>\n<p>Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2\/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I\/II clinical trials in the US, <span class=\"xn-location\">Australia<\/span>, and <span class=\"xn-location\">China<\/span>. HQP1351, the company&#8217;s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia has been granted an Orphan Drug Designation (ODD) and a Fast Track designation by the US Food and Drug Administration (FDA), and a New Drug Application for the drug candidate has been submitted in <span class=\"xn-location\">China<\/span>. To date, Ascentage Pharma has obtained a total of six ODDs from the FDA for four of the company&#8217;s investigational drug candidates.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p>The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN00658&amp;sd=2020-11-23\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/ascentage-pharma-receives-approvals-for-two-phase-ibii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china-301178783.html\">http:\/\/www.prnewswire.com\/news-releases\/ascentage-pharma-receives-approvals-for-two-phase-ibii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china-301178783.html<\/a><\/p>\n<p>SOURCE  Ascentage Pharma<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CN00658&amp;Transmission_Id=202011230532PR_NEWS_USPR_____CN00658&amp;DateId=20201123\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SUZHOU, China and ROCKVILLE, Md., Nov.\u00a023, 2020 \/PRNewswire\/ &#8212; Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved two Phase Ib\/II clinical studies of its novel Bcl-2 inhibitor APG-2575; one for APG-2575 as a single agent or in combination with ibrutinib\/rituximab for the treatment of patients with Waldenstr\u00f6m macroglobulinemia (WM), and the other one for APG-2575 as a single agent or in combination with lenalidomide\/dexamethasone for the treatment of patients with multiple myeloma (MM). APG-2575 is a novel, orally administered Bcl-2\u2012selective inhibitor being developed by Ascentage &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ascentage Pharma Receives Approvals for Two Phase Ib\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386438","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ascentage Pharma Receives Approvals for Two Phase Ib\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma Receives Approvals for Two Phase Ib\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SUZHOU, China and ROCKVILLE, Md., Nov.\u00a023, 2020 \/PRNewswire\/ &#8212; Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved two Phase Ib\/II clinical studies of its novel Bcl-2 inhibitor APG-2575; one for APG-2575 as a single agent or in combination with ibrutinib\/rituximab for the treatment of patients with Waldenstr\u00f6m macroglobulinemia (WM), and the other one for APG-2575 as a single agent or in combination with lenalidomide\/dexamethasone for the treatment of patients with multiple myeloma (MM). APG-2575 is a novel, orally administered Bcl-2\u2012selective inhibitor being developed by Ascentage &hellip; Continue reading &quot;Ascentage Pharma Receives Approvals for Two Phase Ib\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T10:35:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/891219\/Ascentage_Pharma_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ascentage Pharma Receives Approvals for Two Phase Ib\\\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China\",\"datePublished\":\"2020-11-23T10:35:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\\\/\"},\"wordCount\":1365,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/891219\\\/Ascentage_Pharma_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\\\/\",\"name\":\"Ascentage Pharma Receives Approvals for Two Phase Ib\\\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/891219\\\/Ascentage_Pharma_Logo.jpg\",\"datePublished\":\"2020-11-23T10:35:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/891219\\\/Ascentage_Pharma_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/891219\\\/Ascentage_Pharma_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma Receives Approvals for Two Phase Ib\\\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ascentage Pharma Receives Approvals for Two Phase Ib\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma Receives Approvals for Two Phase Ib\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China - Market Newsdesk","og_description":"PR Newswire SUZHOU, China and ROCKVILLE, Md., Nov.\u00a023, 2020 \/PRNewswire\/ &#8212; Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved two Phase Ib\/II clinical studies of its novel Bcl-2 inhibitor APG-2575; one for APG-2575 as a single agent or in combination with ibrutinib\/rituximab for the treatment of patients with Waldenstr\u00f6m macroglobulinemia (WM), and the other one for APG-2575 as a single agent or in combination with lenalidomide\/dexamethasone for the treatment of patients with multiple myeloma (MM). APG-2575 is a novel, orally administered Bcl-2\u2012selective inhibitor being developed by Ascentage &hellip; Continue reading \"Ascentage Pharma Receives Approvals for Two Phase Ib\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T10:35:53+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/891219\/Ascentage_Pharma_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ascentage Pharma Receives Approvals for Two Phase Ib\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China","datePublished":"2020-11-23T10:35:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/"},"wordCount":1365,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/891219\/Ascentage_Pharma_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/","name":"Ascentage Pharma Receives Approvals for Two Phase Ib\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/891219\/Ascentage_Pharma_Logo.jpg","datePublished":"2020-11-23T10:35:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/891219\/Ascentage_Pharma_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/891219\/Ascentage_Pharma_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-receives-approvals-for-two-phase-ib-ii-clinical-studies-of-the-bcl-2-inhibitor-apg-2575-for-the-treatment-of-waldenstrom-macroglobulinemia-and-multiple-myeloma-in-china\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma Receives Approvals for Two Phase Ib\/II Clinical Studies of the Bcl-2 Inhibitor APG-2575 for the Treatment of Waldenstr\u00f6m Macroglobulinemia and Multiple Myeloma in China"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386438"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386438\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}